Medicinova (MNOV) Current Deferred Revenue (2011 - 2025)

Medicinova's (MNOV) quarterly Current Deferred Revenue came in at $370160.0 in Q4 2025, down 29.07% on a QoQ basis from $521899.0 in Q3 2025.

Medicinova (MNOV) Current Deferred Revenue (2011 - 2025) Analysis & Trends

Medicinova (MNOV) has 4 years of Current Deferred Revenue data on file, last reported at $370160.0 in Q4 2025.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $370160.0 in Q4 2025; TTM through Dec 2025 was $370160.0, a N/A change from a year earlier, with the FY2025 full-year figure at $370160.0, changed N/A from the prior year.
Current Deferred Revenue for Q4 2025 stood at $370160.0, down from $521899.0 in the prior quarter.
Over the last five years, Current Deferred Revenue for MNOV reached as high as $1.7 million in Q3 2021 and fell as low as $370160.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00

Download Data